312 related articles for article (PubMed ID: 23676890)
1. Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo.
Kao CY; Yang SJ; Tao MH; Jeng YM; Yu IS; Lin SW
Thromb Haemost; 2013 Aug; 110(2):244-56. PubMed ID: 23676890
[TBL] [Abstract][Full Text] [Related]
2. FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis.
Kao CY; Lin CN; Yu IS; Tao MH; Wu HL; Shi GY; Yang YL; Kao JT; Lin SW
Thromb Haemost; 2010 Aug; 104(2):355-65. PubMed ID: 20539913
[TBL] [Abstract][Full Text] [Related]
3. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
[TBL] [Abstract][Full Text] [Related]
4. Generation of a novel factor IX with augmented clotting activities in vitro and in vivo.
Lin CN; Kao CY; Miao CH; Hamaguchi N; Wu HL; Shi GY; Liu YL; High KA; Lin SW
J Thromb Haemost; 2010 Aug; 8(8):1773-83. PubMed ID: 20492477
[TBL] [Abstract][Full Text] [Related]
5. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.
Crudele JM; Finn JD; Siner JI; Martin NB; Niemeyer GP; Zhou S; Mingozzi F; Lothrop CD; Arruda VR
Blood; 2015 Mar; 125(10):1553-61. PubMed ID: 25568350
[TBL] [Abstract][Full Text] [Related]
6. Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
Samelson-Jones BJ; Finn JD; George LA; Camire RM; Arruda VR
JCI Insight; 2019 Jun; 5(14):. PubMed ID: 31219805
[TBL] [Abstract][Full Text] [Related]
7. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
[TBL] [Abstract][Full Text] [Related]
8. Genetic modification of donor hepatocytes improves therapeutic efficacy for hemophilia B in mice.
Wu YM; Kao CY; Huang YJ; Yu IS; Lee HS; Lai HS; Lee PH; Lin CN; Lin SW
Cell Transplant; 2010; 19(9):1169-80. PubMed ID: 20412633
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua.
Nair N; De Wolf D; Nguyen PA; Pham QH; Samara-Kuko E; Landau J; Blouse GE; Chuah MK; VandenDriessche T
Blood; 2021 May; 137(21):2902-2906. PubMed ID: 33735915
[TBL] [Abstract][Full Text] [Related]
10. Characterisation of factor IX with a glycine-to-valine missense mutation at residue 190 in a patient with severe haemophilia B.
Kao CY; Lin CN; Yang YL; Hamaguchi N; Yang SJ; Shen MC; Kao JT; Lin SW
Thromb Haemost; 2011 Apr; 105(4):616-26. PubMed ID: 21301787
[TBL] [Abstract][Full Text] [Related]
11. An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice.
Begbie ME; Mamdani A; Gataiance S; Eltringham-Smith LJ; Bhakta V; Hortelano G; Sheffield WP
Thromb Haemost; 2005 Dec; 94(6):1138-47. PubMed ID: 16411385
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.
Finn JD; Nichols TC; Svoronos N; Merricks EP; Bellenger DA; Zhou S; Simioni P; High KA; Arruda VR
Blood; 2012 Nov; 120(23):4521-3. PubMed ID: 22919027
[TBL] [Abstract][Full Text] [Related]
13. Expression and Characterization of Gly-317 Variants of Factor IX Causing Variable Bleeding in Hemophilia B Patients.
Lu Q; Yang L; Manithody C; Wang X; Rezaie AR
Biochemistry; 2015 Jun; 54(24):3814-21. PubMed ID: 26023895
[TBL] [Abstract][Full Text] [Related]
14. Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
Nummi V; Jouppila A; Lassila R
Int J Lab Hematol; 2017 Aug; 39(4):359-368. PubMed ID: 28406575
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Adeno-Associated Viral Vectors Expressing Human Coagulation FIX-E456H Variant in Hemophilia B Mice.
Le Quellec S; Dane AP; Barbon E; Bordet JC; Mingozzi F; Dargaud Y; Marais T; Biferi MG; Négrier C; Nathawani AC; Enjolras N
Thromb Haemost; 2019 Dec; 119(12):1956-1967. PubMed ID: 31659733
[TBL] [Abstract][Full Text] [Related]
16. Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice.
Cantore A; Nair N; Della Valle P; Di Matteo M; Màtrai J; Sanvito F; Brombin C; Di Serio C; D'Angelo A; Chuah M; Naldini L; Vandendriessche T
Blood; 2012 Nov; 120(23):4517-20. PubMed ID: 23043073
[TBL] [Abstract][Full Text] [Related]
17. Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche T; Chuah MK
Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
[TBL] [Abstract][Full Text] [Related]
18. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.
Zhang R; Wang Q; Zhang L; Chen S
Front Med; 2015 Mar; 9(1):90-9. PubMed ID: 25663062
[TBL] [Abstract][Full Text] [Related]
19. In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7.
Enjolras N; Perot E; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
Haemophilia; 2015 Jul; 21(4):e317-21. PubMed ID: 25981983
[TBL] [Abstract][Full Text] [Related]
20. Humanization and functional characterization of enhanced coagulation factor IX variants identified through ancestral sequence reconstruction.
Coyle CW; Knight KA; Brown HC; George SN; Denning G; Branella GM; Childers KC; Spiegel PC; Spencer HT; Doering CB
J Thromb Haemost; 2024 Mar; 22(3):633-644. PubMed ID: 38016519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]